Biotherapy monitoring company THERADIAG (Paris:ALTER) announced on Monday that it generated 2022 annual revenue of of EUR12.2m over the year to 31 December 2022, compared to EUR11.1m in 2021.

This is an increase of 9.7% and is reportedly in line with the company's roadmap published on 27 October 20221.

Theradiag said that it had a cash position of EUR6.4m as at 31 December 2022, compared with EUR7.1m at 31 December 2021 and EUR6.0m at 30 June 30 2022.

The growth in Theranostics activity was a result of recurring sales of i-Tracker tests, with the range having been expanded and adapted to these i-Track10 and equivalent systems. The company added that the worldwide active installed base of these systems has doubled since the end of 2021.

A specialist in in vitro diagnostics of autoimmune diseases and Theranostics, the company has been developing, manufacturing and marketing innovative in vitro diagnostic (IVD) tests for over 30 years.